Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1299-1310

  Heo, Kyung Sun ^a,c   Le, Nhat Tu ^a,c   Cushman, Hannah J ^a   Giancursio, Carolyn J ^a   Chang, Eugene ^a   Woo, Chang Hoon ^a,d   Sullivan, Mark A ^a   Taunton, Jack ^b   Yeh, Edward T H ^c   Fujiwara, Keigi ^a,c   Abe, Jun Ichi ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Yeungnam University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SENTRIN SUMO SPECIFIC PROTEASE 2; SERINE THREONINE KINASE P90RSK; SUMO PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CYSTEINE PROTEINASE; S6 KINASE; SENP2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; LIPID STORAGE; LIQUID CHROMATOGRAPHY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SUMOYLATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD FLOW; CAROTID ARTERY; CELL CULTURE; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CAROTID ARTERIES; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; ENZYME ACTIVATION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 7; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; REGIONAL BLOOD FLOW; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53; VASCULITIS;

EID: 84924071900     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76453     Document Type: Article

References (31)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.
2. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241.
3. Heo KS, et al. PKCzeta mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol. 2011;193(5):867-884.
4. Heo KS, Fujiwara K, Abe J. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ J. 2011;75(12):2722-2730.
5. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035-2042.
6. Chang E, et al. MK2 SUMOylation regulates actin filament remodel ing and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood. 2011;117(8):2527-2537.
7. Yu J, et al. RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. J Biol Chem. 2012;287(17):13752-13760.
8. Woo CH, et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induce d antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res. 2008;102(5):538-545.
9. Hilgarth RS, Murphy LA, Skaggs HS, Wilkerson DC, Xing H, Sarge KD. Regulation and function of SUMO modification. J Biol Chem. 2004;279(52):53899-53902.
10. Geiss-F riedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8(12):947-956.
11. Heo KS, et al. De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regul ates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res. 2013;112(6):911-923.
12. Nigro P, et al. PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood. 2010;116(11):1971-1979.
13. Le NT,et al A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis Circulation. 2013 127 4, 486-499.
14. Le NT, et al. p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res. 2012;110(4):536-550.
15. Itahana Y, Yeh ET, Zhang Y. Nucleocytoplasmic shuttling modulates activity and ubiquitinationdependent turnover of SUMO-specific protease 2. Mol Cell Biol. 2006;26(12):4675-4689.
16. Iiyama K, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites p redisposed to lesion formation. Circ Res. 1999;85(2):199-207.
17. Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML. VE-Cadherin-Cre-ERT2 transgenic mouse: a mod el for inducible recombination in the endothelium. Dev Dyn. 2006;235(12):3413-3422.
18. Dunn J, et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. J Clin Invest. 2014;124(7):3187-3199.
19. Nam D, et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol. 2009;297(4):H1535-H1543.
20. Merino H, Parthasarathy S, Singla DK. Partial ligation-induced carotid artery occlusion induces leukocyte recruitment and lipid accumulatio n-A shear stress model of atherosclerosis. Mol Cell Biochem. 2013;372(1):267-273.
21. Gerloff J, Korshunov VA. Immune modulation of vascular resident cells by Axl orchestrates carotid intima-media thickening. Am J Pathol. 2012;180(5):2134-2143.
22. Barbas CF III, Burton DR, Scott JK, Silverman GJ. Phage Display: A Laboratory Manual. New York, New York, USA: Cold Spring Harbor Laboratory Press; 2011.
23. Haidaris CG, et al. Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens. J Immunol Methods. 2001;257(1):185-202.
24. Shea C, Bloedorn L, Sullivan MA. Rapid isolation of single-chain antibodies for structural genomics. J Struct Funct Genomics. 2005;6(2):171-175.
25. Takahashi M, Berk BC. Mitogen-Activated protein kinase (ERK1/2) activation by shear stress and adhesion in endothelial cells. Essential role for a herbimycin-sensitive kinase. J Clin Invest. 1996;98(11):2623-2631.
26. Reinhart-Ki ng CA, Fujiwara K, Berk BC. Physiologic stress-mediated signaling in the endothelium. Methods Enzymol. 2008;443:25-44.
27. Abe J, Takahashi M, Ishida M, Lee JD, Berk BC. cASrc is req uired for oxidative stress-mediated activation of big mitogen-Activated protein kinase 1. J Biol Chem. 1997;272(33):20389-20394.
28. Galluzzi L, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009;16(8):1093-1107.
29. Ding B, et al. Left ventricular hypertrophy in ascending aortic stenosis mice: anoikis and the progression to early failure. Circulation. 2000;101(24):2854-2862.
30. Jiang M, Chiu SY, Hsu W. SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ. 2011;18(6):1005-1015.
31. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol. 2002;160(6):2145-2155.